USFDA concludes inspection at Gland Pharma’s Hyderabad facility

4 Jan 2023 , 02:12 PM

Gland Pharma Limited informed that the USFDA has indicated the closure of inspection.

The company stated in an exchange filing that following the pre-market inspection for medical devices covering the USFDA’s Quality System/Current Good manufacturing practice regulations at its Dundigal Facility at Hyderabad from August 22, 2022 to August 25, 2022, it has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, USFDA.

This report indicates closure of the inspection conducted the company’s facility.

Following this development, Gland Pharma was trading at Rs1,575.15 apiece, against its previous close of Rs1,575.75 on NSE. The counter touched an intraday high and low of Rs1,598.80 and Rs1,566 respectively.

For feedback and suggestions, write to us at [e-mail]